echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > The antibody drug Polivy, which targets CD79a, is recommended by NICE for the treatment of relapsed or resuscable large B-cell lymphoma.

    The antibody drug Polivy, which targets CD79a, is recommended by NICE for the treatment of relapsed or resuscable large B-cell lymphoma.

    • Last Update: 2020-10-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The National Institute for Health and Care Excellence (NICE) recommends combining Roche's antibody drug polyvy (polatuzumab vedotin) with rituximab and bendamustine to treat diffuse large B-cell lymphoma (DLBCL).
    CD79b is a component of B-cell antigen receptors, has a high specificity, has become a new target for the treatment of B-cell lymphoma after CD20.
    : According to NICE, there are about 4,800 DBCL patients in the UK, of whom about 530 are eligible for Polivy combined treatment.
    , the drug combination will be available to patients with relapses or non-responsiveness after first-line treatment and who are not suitable for stem cell transplants.
    in clinical trials in DLBCL patients, Polivy had a 40 percent full remission rate with Rituxan/Benzamostin, compared with 18 percent in the control group.
    , the total survival of patients increased from 4.7 months to 11.8 months.
    new treatment is good news for patients and clinicians, given the poor prognostic prognosticity of relapsed or resuscable DLBCL.
    's drug combination was the first to show overall survival advantage in this class of patients.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.